C loza pine is th e first a n tipsyc ho tic age n t wit h proven superior ity over conve nti on al a n tipsyc ho tics in te rm s of it s efficacy in t reatm ent-resist ant patie nts (1,2). In pati ents with poor or parti al resp on se to co nve n tional neu rol ep tics, cloza pine is th e treatm ent of choice . We wish to rep ort a nd to di scuss a cas e of t he rapid a nd subs ta n tia l improvement of a patient who was started on c1ozapi ne.
PRESENT I IG PROBLEM AND PATIENT DESCRIPTION Ms. C. was a 34 year old whit eJ ewish fem al e with 13 yea r hist or y of schizoaffective di sorder. At th e tim e of admi ssion th e pati ent report ed a ud itory hallu cin a tions, refer entia l delusions (th e patient felt that other peop le were mak ing refe rence to her), a nd th e bel ief that sh e was abl e to read th e minds of peopl e a ro u nd her. T he Leo Sh er , M.D. is a fellow at th e National Inst itu te of Ment al Health , Bethesda , Ma ryla nd. At th e tim e of writ ing this article, he was a resid ent a t Hill sid e H ospit al , Psychi patient also reported sa d mood a nd so me a nx ie ty. She was tea rfu l with a constricted a ffect. Ms. C . showed good in sight int o he r illn ess (s he was aware of her illn ess, a nd und erst ood th at her sym pto ms a nd soc ia l probl em s were du e to her own di st urbances), a nd expressed a strong d esi re to ge t rid of he r sym ptoms. Th is, d esp it e t he fact th at th e male voice whi ch was " ta lking to he r" sou nd ed fri endly. (She s ta te d that th e a bility to hear this voice was a bno rmal.) During th e ini tia l in te rview Ms. C . also di spl a yed some d ep endent features including th e need s for he r parents to assum e res pons ibility for decision s in her life. We had a n opport u nity to in te rview t he pati ent 's parents a nd learned th at th e patient always had d ep e nd e nt traits.
BACKGRO UND INFORMATION
Ms . C. did well academically in th e Elementary,junior Hi gh , an d Hi gh Schools. Sh e skipped two school years and grad ua te d from th e Hi gh Schoo l in 10 yea rs instead of 12 years. Sh e e n te re d th e College, a nd she was close to com ple ting he r Bachelor Degr ee, wh en at th e age of 21, Ms . C. d eveloped psych otic sym pto ms includ ing a ud itory hallucin ation s a nd ideas of referen ce. H er level of fu nct ion ing d eclin ed consid e ra bly, and th e patient had to drop ou t of th e College . T he pati en t was hospitali zed on ce a t th e tim e of her fir st break , and th en she has bee n in out pa tient treatm ent for 13 yea rs . The cou rs e of her illn ess was som ewhat unusual : it wen t for 13 years fro m onse t to th e first co ns ide ra ble rel ap se. She has been on ha lop eri dol for a lon g ti m e wit h a part ial res po nse (t he level of he r social fun cti oni ng was low, and, some times, she had mild psych ot ic sym pto ms) . Six months prior to ad m ission, th e pa ti ent 's co nd ition d et eriorat ed , she d evelop ed persist e nt a ud itory hallucin ation s a nd referential d elu sion s, and she was switc h ed from hal ope ridol to fluph en azine. Fluphe naz ine was gradua lly incr eas ed to 40 mglday. Howeve r, th e clinica l res ponse was te m po rary a nd limited . The pat ien t con tinue d to d et e riorat e, a nd he r psychiat rist referred her to th e hospital for inpatient t rea tm en t.
HOSPITAL COU RSE Ms. C . was eva lua te d a nd felt to m eet crite ria for no nres po nse to sta ndard a n tipsyc hotic treatment, a nd was offe red cloz apine t reat m e nt. Sh e was told t ha t cloz apine was a very effec tive drug, it helped many patients, who were part ial respond ers , and that it could improve th e pati ent 's qu ality of life. Ms. C. ag reed with cons id e ra ble e n t husiasm . On th e fir st day of th e t reatm ent she received 12.5 mg of clozapine wh ile fluph en azin e was tap ered to 20 mg. On t he next d ay the pa tie nt repo rte d improvement, s ta ting th at h er a udito ry hallucin ation s we re less d isturbing, a nd th at she was free of th e hallucin ation s for two hou rs in th e morning. On t he fifth day of th e treatm ent, wh en th e clo zapine dose was 25 mg bid a nd fluph e nazine dose contin ue d a t 20 rng/d ay, Ms. C . re ported marked im prove me nt, t he patient stated th at she felt mu ch bette r, tot all y free fro m refere n tial id eas. She rep orted t hat t he hallucin atory voice was quiet, less di stu rbing, a nd a pa rt of t he day she d id not hear it a t all. She a lso felt reli ef from a nxie ty. O ver th e following d ays Ms. C. reported improvement almost every day, sh e tol erated cloza pine well, a nd t hree wee ks aft er her admission she was discharged with very conside ra ble improvem ent. At th e time of discharge patient was not getting fluph enazine, and her clozapine dose was 200 mg /day.
DISCUSSION
This quick and remarkable response to cloza pine treatm ent in thi s patient requires further evalua tion. It ca n be expla ine d in part by a placeb o effect which is probably involv ed in every therapeutic maneuver. A number of fact or s whic h may predict a good response in this patient may include th e patient 's stron g desi re to get better, relatively good insight into h er illness, a relatively high level of ed ucation, the patient's high degree of suggestibility, th e pr es en ce of d ep end ent pe rsonal it y features , th e d esire to be a "good patient," a nd th e fact th at th e m ed icat ion was given by ca ring and confide nt physicians cou ld cont ribute to thi s effect.
The " placebo effec t" is an outstanding exam ple of mind-bod y re la tions hips, a case of transformation of psychological effec ts into biological processes (3, 4) . Pa tien ts with schizophrenia may respond to placebos (5) (6) (7) (8) . A st riking d ep end ence on a placebo in a periodically catatonic schizophrenic wom an has been re por te d in th e lit erature (5). An un expected placebo response was found during a doubl e-blind drug study in a patient with treatment-resistant tardive diskinesia (6). Schulz and colleagu es reported a n exce ssive beta-endorphin response to placebo in schizophren ic patients (7) . Pickar and associates found incr eas es in plasma opi oid ac tivity after the intravenous administration of placebo in patients with sch izoph re nia (8) .
In 1978 Levine a nd as sociates who st ud ied th e a nalge sic effec t of placebo proposed that endorphin rel eas e m edi ates a pla cebo respons e (9). Several stud ies were cond uc te d to test th e hypothesis that beta-endorphins are e ndogenous subst an ces with neuroleptic-like activity and th at di sturbances in th e bet a-endorphin fra gm entation may con t ribu te to th e pathogen esis of psychotic di sord e rs (10) (11) (12) . Thes e studies showed th at e ndor phins ca n poss ess neurol eptic pr op erties. H e nce, it ca n be argued th at placebo m ay ca use a rel eas e of e ndoge nous subs ta nces with neuroleptic-like activity and produce an antipsychotic effec t.
Decr eas e in fluph enazine dos e could also play a part in th e pa ti ent's quick and substantial improvement. Clinical information on th e th erapeutic do sage of antipsychotics remains controversial. It has been proposed that neuroleptics may have a bell-shaped dos e-respons e cu rve (13) . Possibly, in this ca se 20 mg of fluph e nazine per day could give a better clinical response than 40 mg/day. It is also possible t hat decr ease in fluph enazine caused reduction in ex t ra pyram idal sym ptoms, and th e improvement was from the decreas e in th es e symptoms.
Anoth er possible expla na tion can be con nec te d with mon oamin e a nd am ino acid transmission in different brain regions aft er ac ute cloza pine ad m inist rat ion . Th e expe rime n ts on ra ts showed that the acute administration of 10-30 mg/ kg of cloza pine increased dopamine and glutamat e in th e m edial pr efrontal cortex, and produced a gr eater incr ease com pa re d with haloperidol, in ga m ma-am inobutyric ac id efflux within the ventral pa llidum (14) . Th ese change s were obs erved 1-2 hou rs after the clozapine administration. Combined dysfunction of dopamine and N-m et hyl-Daspartate glutamate receptors with th e involv em ent of GABA ergic neurons has bee n implicated in pathophysiological m echanism of sch izophrenia, a nd it has been suggested t ha t som e antipsychotic drugs , including c1ozapine, ca n pr eve nt th ese pat ho log ical changes in the br ain (I5).
There is a possibility that th e original diagnosis was in accurat e. Th e unu su al course of th e patient 's illn ess (it went for 13 years from ons et to fir st se rious rela pse) and the unusually rapid improvement aft er th e inpatient ad m issio n mi gh t be rela ted to th e in correct original di agnosis.
CONCLUSION
Ov er th e past de cad es we have witnessed con sid erab le pro gr ess in th e psychopha rmacological treatment of psychotic disorders. Antipsych oti c m edi cat ions hel p man y patients. Bette r understanding of th e m ech anisms of ac tion of psych ot ro pic drugs may significantly improve patient ca re .
